Lifecore Biomedical
LFCR
93 hedge funds and large institutions have $149M invested in Lifecore Biomedical in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 28 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
18% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 28
8% more funds holding
Funds holding: 86 → 93 (+7)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.19% less ownership
Funds ownership: 83.6% → 83.41% (-0.19%)
32% less capital invested
Capital invested by funds: $220M → $149M (-$71.4M)
95% less call options, than puts
Call options by funds: $21K | Put options by funds: $389K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wynnefield Capital
New York
|
+$7.66M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.38M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$690K |
| 4 |
CSC
Cove Street Capital
El Segundo,
California
|
+$476K |
| 5 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$439K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
ISZO Capital Management
New York
|
-$9.53M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$629K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$605K |
| 4 |
PRCP
Pacific Ridge Capital Partners
Lake Oswego,
Oregon
|
-$568K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$436K |
LFCR Hedge Fund Activity: Q4 2022 in Review
93 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2022, worth a combined $149M — down 32% from $220M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LFCR positions and 3 closed out — a net gain of 7 holders — while 33 added to existing stakes and 28 trimmed.
The largest buyer was Wynnefield Capital, adding an estimated $7.66M. The largest seller was ISZO Capital Management, cutting an estimated $9.53M.
- 93 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2022, up from 86 in Q3 2022.
- Funds reported $149M of Lifecore Biomedical stock for Q4 2022, down 32% quarter-over-quarter.
- 10 funds opened new Lifecore Biomedical positions in Q4 2022 and 3 closed out, a net change of +7 holders.
- The largest Lifecore Biomedical buyer in Q4 2022 was Wynnefield Capital, an estimated $7.66M added.
- The largest Lifecore Biomedical seller in Q4 2022 was ISZO Capital Management, an estimated $9.53M sold.
Based on aggregated 13F filings for Q4 2022.